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Objective: Airway stenoses have been a significant cause of morbidity and mortality after lung transplantation.
We reviewed our 11-year experience with dilatation and silicone stent treatment of airway strictures after lung
transplantation.We adopted this approach after managing the complications of nitinol/wire mesh stents, including
stent fracture, granulation tissue overgrowth, and difficulty with removal.
Methods: Between January of 1996 and December of 2007, 240 patients underwent lung transplantation (132
single lung, 108 double lung; 121 male, 119 female; mean age 49.4  12.9 years). Twenty patients (8.3%) de-
veloped>50% stenosis in 22 airways over 35 to 135 days following surgery. Short and long-segment strictures
were managed with rigid bronchoscopy, mechanical/laser debridement, balloon dilatation, and silicone stent
placement. Mean follow-up was 4.9  3.5 years after stent removal.
Results: The mean time to diagnosis of airway stenosis was 81.5 26.9 days. Pulmonary aspergillosis and pseu-
domonal infection, age less than 45 years, and early rejection correlated with airway stenosis; however, ischemic
time, side of transplant, and preoperative disease did not. Airway patency and symptom improvement were
achieved in 18 of 20 patients. Sixteen patients were able to have their stents removed at a mean of 362.3 
126.4 days with permanent resolution of airway stenosis. Overall survival was similar for patients with and with-
out airway stenosis.
Conclusion: Airway stenosis after lung transplantation can be successfully managed with bronchoscopic dilata-
tion and temporary silicone stent placement. With time, most short and long airway stenoses resolve with atrau-
matic stenting of the affected areas. Removal of stents with permanent airway patency is achievable in most lung
transplant recipients with airway stenosis.T
XSince the first lung transplantation in 1963, advances in op-
erative techniques, immunosuppression, and patient care
have led to improved survival and decreased postoperative
complications for lung transplant recipients. However,
short- and long-segment bronchial stenoses remain a source
of major morbidity and mortality in lung transplant recipi-
ents. It has been reported that perianastomotic stenoses oc-
cur in 12% to 40% and nonanastomotic distal bronchial
stenoses in 2% to 4% of lung transplants.1,2 Effective treat-
ment reduces the impact of these complications. Tradition-
ally, bronchial stenoses after lung transplantation have
been treated with balloon dilatation and expandable nitinol
(nickel-titanium: Ultraflex, Boston Scientific; Galway, Ire-
land) or metal (elastic-coated medical grade 304-stainless
steel: Gianturco, Cook Inc; Letchworth, UK; cobalt-based
stainless steel: Wallstent, Schneider Co; Minneapolis,
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son and Johnson; Warren, NJ) stents.3,4
In our experience with the use of nitinol and wire mesh
stents for bronchial stenosis, we encountered significant dif-
ficulty with 1) granulation tissue overgrowth obstructing the
stent, 2) stent fracture with wires protruding in the airway
that blocked airway flow and the clearance of secretions,
and 3) difficulty with stent removal. The University of Cali-
fornia San Diego has become a referral center for both surgi-
cal and nonsurgical nitinol/wire mesh stent removal, and we
have removed more than 50 of these stents in the last 10
years. Since 1996, we have adopted the approach of mechan-
ical and/or laser debridement, balloon dilatation, followed by
placement of a silicone stent with external studs (Hood Silas-
tic Stent with Posts and Mesh: Hood Laboratories, Pem-
broke, Mass) for the treatment of lung transplant airway
strictures. In this article, we review our experience with
this approach with an emphasis on functional improvement,
long-term outcome, and permanent resolution of stenosis.
MATERIALS AND METHODS
Patients and Operative Technique
We reviewed the data from a consecutive series of 240 patients who un-
derwent lung transplantation between January of 1996 and December of
2007. This series consisted of 132 single lung transplants (SLTs) and 108
double lung transplants (DLTs), for a total of 348 anastomoses. Review
of patient data that comprises this article was approved by the University
of California San Diego institutional review board in February of 2008.ardiovascular Surgery c Volume 136, Number 6 1569
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T
XAbbreviations and Acronyms
DLT ¼ double lung transplant
FEV1 ¼ forced expiratory volume in 1 second
FVC ¼ forced vital capacity
IV ¼ intravenously
SLT ¼ single lung transplant
The University of California San Diego institutional review board has
waived the requirement for individual patient consent for this retrospective
analysis. Donor organ procurement and lung preservation were performed
as previously described.5 Before 2004, Euro-Collins solution supplemented
with 50% dextrose solution and magnesium sulfate was used for retrievals;
after 2004, Perfadex solution (Vitrolife; Englewood, Colo) was used. Dur-
ing the lung transplant procedure, bronchial anastomoses were done with
the shortest length of donor bronchus (1 ring from upper lobe takeoff)
and recipient bronchus (within 1–2 rings of carina). All anastomoses were
performed with an end-to-end technique using a continuous nonabsorbable
monofilament (3-0 polypropylene) suture.6 Cardiopulmonary bypass was
used in all DLTs, whereas 31 of 132 SLTs were performed with cardiopul-
monary bypass.
Immunosuppression and Infection Prophylaxis
Triple drug immunosuppression therapy was instituted within 2 hours
before surgery and consisting of FK506: 5 mg orally before surgery, 0.1
mg/h intravenously (IV) administered after surgery (or oral FK506 twice
daily once the patient was eating) with titration of dose to a blood level of
20 to 25 ng/mL in the first week and 15 to 20 ng/mL thereafter; methylpred-
nisolone: 500 mg IV immediately after graft perfusion followed by 125 mg
IV every 8 hours for 3 doses and institution of 0.2 mg/kg/d oral dosing on
day 7; and mycophenolate mofetil: 1 g orally before surgery, 500 to 1000
mg orally twice per day thereafter, maintaining a white blood cell count
greater than 4000/mL. Before 2001, azathioprine was used in lieu of myco-
phenolate mofetil with dosing of 2mg/kg orally before surgery and 2mg/kg/
d IV or orally thereafter with adjustment to maintain a white blood count
greater than 4000/mL.
Perioperative antibiotics were routinely administered for the first 48
hours after transplantation and then adjusted on the basis of intraoperative
and donor culture data. Management of bacterial infections was based on
culture results. Before 2004, fungal prophylaxis consisted of treatment
with inhaled amphotericin B and oral itraconazole; subsequent to this, pro-
phylaxis consisted of treatment with inhaled amphotericin B and oral vori-
conazole. For fungal infections (tracheobronchitis, pneumonia, isolated
anastomotic infection) before 2004, treatment consisted of IV amphotericin
B; for fungal infections subsequent to this, oral voriconazole and either
caspofungin or micafungin were used. Duration of therapy was directed
by patient response, radiographic findings, and appearance of the airway/
anastomosis by bronchoscopic visualization.
Stricture Classification, Bronchial Dilatation, and
Stent Placement
Patients were evaluated by bronchoscopy when there was clinical, radio-
graphic, or spirometric evidence of respiratory decline. Bronchial strictures
were classified as follows: type 1, anastomotic: short segment, localized to
within 1.0 cm of the suture line; type 2, anastomotic: long segment, encom-
passing the anastomosis and more than 1.0 cm of contiguous bronchus from
the suture line; type 3, nonanastomotic bronchial or branch location; and
type 4, diffuse bronchial stenosis (Table 1). Balloon dilatation and stenting
were accomplished with the patient under general anesthesia using rigid
bronchoscopy (8–12 mm Dumon-Harrell rigid ventilating bronchoscope,
Bryan Corporation; Woburn, Mass). Balloon dilators (Ultra-thin Diamond1570 The Journal of Thoracic and Cardiovascular S[single-stage balloon dilatation], Boston Scientific, Watertown, Mass; and
CRE Pulmonary Balloon Dilatation Catheter [3-stage balloon dilatation],
Boston Scientific Microvasive, Galway, Ireland), sizes from 4 to 15 mm,
were inflated using a hand injector to the appropriate pressure based on
the manufacturers’ recommendations for 30 to 60 seconds. Excess granula-
tion tissue was removed by forceps or with the use of the yttrium-aluminum-
garnet laser through the rigid bronchoscope.
The length and diameter of the silicone stent were chosen on the basis of
direct bronchoscopic examination of the post-dilatation airway diameter.
Themost common stent size used had a diameter of 10 to 12mmand a length
of 2 to 4 cm. For stenotic airways where there was significant size discrep-
ancy between proximal and distal extents, 2-step stents with different prox-
imal and distal diameters (Hood Silastic 2-step Stent with Posts and Mesh:
Hood Laboratories) were used. Stents that would potentially cover the upper
lobe bronchus were modified with a 6-mm punch hole for the upper lobe or-
ifice. Each stent was folded into the stent applicator so that its distal extent
was just proximal to the bevel of the rigid bronchoscope, positioned by di-
rect visualization below the area of stenoses, and deployed by withdrawing
the scopewhile pushing the stent out over the stenosis.Minor adjustments in
stent location were done with alligator forceps. Patients with type 2 and 4
strictures that spanned a lobar bronchus/bronchi had a stent placed that
was specifically contoured with an opening(s) on its side allowing for pa-
tency of the lobar opening(s). Rigid and flexible bronchoscopy were used
to confirm stent placement and clear postobstructive secretions.
Stent removal was performed under general anesthesia by grasping the
proximal edge of the stent with a rigid alligator forceps through a rigid bron-
choscope. The alligator forceps were then turned coaxially until the stent
folded in and the proximal portion could be pulled up to the rigid broncho-
scope. The bronchoscope, forceps, and stent were then removed together.
The rigid bronchoscope was inserted again and in combination with flexible
bronchoscopy was used to evaluate the patency of the airway.
Statistical Methods
Continuous data are expressed as means  standard deviation through-
out the text and figures. Nominal variables are expressed as percentages.
In the ‘‘Results’’ section, nominal variables were analyzed by a 2-sided
Fisher’s exact test analysis. Preoperative and postoperative forced expira-
tory volume in 1 second (FEV1), forced vital capacity (FVC), and FEV1/
FVCwere compared using a paired 1-sidedWilcoxon rank-sum test. All sta-
tistical analyses were performed using R 2.6.2 (R Foundation for Statistical
Computing, Vienna, Austria).
RESULTS
A total of 348 anastomoses at risk were reviewed in 240
patients (132 SLT, 108 DLT). Twenty-two bronchial steno-
ses (6.3%) occurred in 20 patients. Patient demographics,
type of bronchial narrowing, and interval to treatment of
complications are described in Table 1. Eight patients had
chronic obstructive airway disease, 6 patients had cystic
fibrosis, 3 patients had idiopathic pulmonary fibrosis, 3
patients had bronchiectasis, 1 patient had lymphangiomyo-
matosis, and 1 patient had eosinophilic granulomatosis. Prin-
cipal signs and symptoms were dyspnea in 80%, respiratory
distress in 5%, pneumonia in 20%, and respiratory failure
requiring ventilator support in 10%. A decline in FEV1
was noted in 85% of patients before diagnostic bronchos-
copy. The interval to the occurrence of an airway stenosis re-
quiring treatment interventionwas 81.5 26.9 days, ranging
from 35 to 135 days after transplantation for all patients. A
spectrum of different airway stenoses were seen. Fifty-foururgery c December 2008
Thistlethwaite et al Cardiothoracic TransplantationTABLE 1. Classification of Lung Transplant Stenosis Type and Demographics
DLT, Double lung transplant; SLT, single lung transplant. *2 DLT patients had bilateral stenoses.T
Xone-half percent of strictures (12/22) were limited to the
bronchial anastomosis (short stenosis, type 1), whereas
22.7% of strictures (5/22) encompassed the anastomosis
and extended more than 1 cm into the donor bronchial tree,
often extending across the upper lobe orifice on the right or
left side (long stenosis, type 2). A small proportion of steno-
ses (13.6%; 3/22) were found to be remote to the bronchial
anastomoses, all in the bronchus intermedius on the right
(distal stenosis, type 3), whereas 9.1% of strictures (2/22)
were classified as diffuse bronchial stenosis spanning at least
2 lobar orifices (long and diffuse stenosis, type 4). There was
no correlation between donor ischemic time and side of
transplant with the development of stenosis, although more
diffuse (type 2 and 4) bronchial stenoses tended to predom-
inate on the right side. There was no clear correlation be-
tween the underlying disease and the type of stenosis,
except that all 3 cases of type 3 stenosis occurred in patients
with cystic fibrosis. Both patients with type 4 disease had
prolonged hypotension in the immediate postoperative
period. Whether this factor contributes to the development
of diffuse airway injury is not clear.
Several clinical parameters were found to be associated
with airway stenosis after lung transplantation, includingThe Journal of Thoracic and CAspergillus fumigatus or actinomyces infection (18/20
patients with stenosis; [90%], compared with 9/220 patients
without stenosis; [4.1%],P<.001), age less than45 years (13
patients with stenosis; [65%], comparedwith 65/220 patients
without stenosis; [29.5%], P¼ .002), Pseudomonas aerugi-
nosa infection (6/20 patients with stenosis; [30%], compared
with 11/220 patients without stenosis; [5.0%],P¼ .001), and
first rejection within 3 months of transplant (6/20 patients
with stenosis; [30%], compared with 5 of 220 patients with-
out stenosis; [2.3%], P< .001) (Figure 1). Factors such as
preoperative steroid use, reflux symptoms, preoperative dis-
ease type, and ventilator support more than 48 hours did
not correlate with the development of airway stenosis.
Five patients had granulation or fibrinous infected tissue
at their anastomoses contributing to initial airway narrow-
ing, which was treated with mechanical or yttrium-alumi-
num-garnet laser debridement before balloon dilatation.
All bronchial strictures were treated with at least 1 session
of balloon dilatation before stenting (Table 2). Nine patients
required 2 to 3 sequential balloon dilatations, and 2 patients
required 3 to 5 sequential dilatations. All individuals experi-
enced either symptomatic improvement (18 patients) or
reduced ventilatory support (2 patients).ardiovascular Surgery c Volume 136, Number 6 1571
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T
XFIGURE 1. Clinical factors associated with bronchial stenosis.Data on pulmonary function tests immediately before
dilatation and stent placement and immediately after stent
removal are detailed in Table 3. Mean FEV1, FVC, and
FEV1/FVC at the time of diagnosis of bronchial stenosis
were 1.95 L/s (range 0.6–3.86 L), 2.91 L/s (range 1.21–
4.86 L), and 66.3%, respectively. After the stents were re-
moved, mean FEV1 was 2.76 L (mean increase of 41.5%
or 0.81 L, P ¼ .003), mean FVC was 3.42 L (mean increase
of 17.5% or 0.51 L, P ¼ .009), and mean FEV1/FVC was
81.3% (P ¼ .02).
On average, patients underwent flexible bronchoscopy
every 3 to 4 months after stent placement. Although secre-
tions were found within stents, only 2 patients required
emergency bronchoscopy for secretion obstruction, over
a total follow-up of 16.8 patient years (Table 2). Three stents
required repositioning at least once over the same follow-up
period. Five stenoses (22.7%) required a longer stent than
originally placed, and this upsizing was done over a mean
time frame of 6.3  4.7 months. Granulation tissue was de´-
brided from the airway next to stent orifices in 2 patients,
both with type 2 strictures at a mean of 274  85 days after
stent placement. Between approximately 10 and 12 months
after stent placement, all stents were removed and the air-
ways were inspected. Twelve anastomoses were widely pat-
ent and required no further intervention at this time, whereas
9 anastomoses required repeat stent insertion after airway
evaluation (1 patient died during this interval). Thereafter,
every 4 months, stents were removed and the airway was re-
examined for patency until permanent stent removal was
achieved.
The majority of patients who had aggressive early stent
placement and treatment of underlying fungal/bacterial in-
fections had resolution of their bronchial stenoses with
permanent stent removal within 362.3  126.4 days (range1572 The Journal of Thoracic and Cardiovascular Su185–567 days). All but 4 patients had successful removal
of their stents with resolution of their bronchial strictures.
Two individuals died with a bronchial stent in place. One
patient had persistent left main bronchial stenosis that on
autopsy (after death from pneumonia and hepatic failure)
was found to have been large cell lymphoma infiltrating
the airway wall compressing the bronchial lumen at that
site, whereas the other patient, who had diffuse bronchial
stenosis treated with 2 stents in parallel in the right bron-
chial tree, died of chronic rejection and pneumonia. Two
recent patients in our series currently have stents in place
that have not been removed yet. At a mean follow-up of
4.9  3.5 years after stent removal, all patients had patent
airways with resolution of stricture requiring no further
treatment.
Overall, 3-year survival of transplant patients without ste-
nosis during the study period was 68% (150/220), compared
with 85% (17/20) for patients with stenosis/stent (P ¼
.058). Although there is no statistical difference in survival,
the results suggest a possible trend toward survival benefit.
The conditional 3-year survival of patients without stenosis
who lived more than 3 months posttransplant was 87%. In
comparing long-term outcome of the 2 patient groups, the
use of conditional survival may be more appropriate because
deaths in the immediate posttransplant period were related to
early complications, before the development of bronchial
stenosis.
DISCUSSION
Airway stenoses are a continuing problem in lung trans-
plant recipients. Previous studies have reported an incidence
of perianastomotic stenosis in up to 40% and nonanasto-
motic distal bronchial stenoses in up to 4% of patients after
lung transplantation.1,2 However, these studies did notrgery c December 2008
Thistlethwaite et al Cardiothoracic TransplantationTABLE 2. Airway Manipulations Before and During Stenting
All Types Type 1 Type 2 Type 3 Type 4
Dilatations per patient
prior to stenting
1.8  1.1 1.5  0.8 2.2  1.6 2.3  1.4 2.0  1.4
# Patients requiring stent
repositioning or upsizing
8 4/8 (50%) 1/8 (12.5%) 1/8 (12.5%) 2/8 (25%)
# Patients requiring emergency
bronchoscopy for secretion
clearance
2 0 1/2 (50%) 0 1/2 (50%)
Mean time from diagnosis
to stent removal (days)
362.3  126.4 386.1  139.8 313.2  94.3 354.5  149.2 NR
Mean length of follow-up after
stent removal (years)
4.9  3.5 4.9  3.5 4.0  4.0 7.7  1.4 NR
Stent
Average diameter 10 mm 10 mm 10 mm 10 mm
Average length 3 cm  6 mm
opening for
RUL orifice
3 cm  6 mm
opening for
RUL orifice
3 cm 4 cm
Data expressed as mean  standard deviation or number of patients affected/total number of patients (%). NR, Not removed.T
Xdifferentiate clinically significant stenosis from mild non-
progressive anastomotic narrowing that rarely results in clin-
ical compromise. On the basis of our experience in both
transplant recipients and patients without transplant, airway
narrowing without concomitant underlying lung disease
rarely causes clinical symptoms unless the occlusion ex-
ceeds 50%. By using this criterion, we report a 6.3%
incidence of clinically significant airway stenosis in a
single-center experience of 240 consecutive lung transplant
recipients.
Traditionally, bronchial stenoses after lung transplanta-
tion have been treated with balloon dilatation and expand-
able nitinol or stainless steel mesh stents. They have been,
and are still, a popular choice in many centers for the man-
agement of airway stenoses, largely because of the ease of
stent placement. However, our experience, as well as others,
indicated that wire mesh stents are associated with signifi-
cant and frequent complications, including 1) granulation
tissue overgrowth within stent interstices,7 2) stent fracture
with wires protrusion,8 3) stent erosion through the airway,9
4) longitudinal stent collapse,10 5) and trouble with stent
removal.11
Because of these problems, we chose to use studded sil-
icone stents to manage our lung transplant recipients with
bronchial stenosis. Several unique features of the Hood
stent design include 1) a self-expanding capacity making
it easy to deploy; 2) a thin wall structure providing a larger
lumen than the other silicone stents; 3) the presence of
silicone studs on the surface of the outer diameter, which ef-
fectively reduce stent migration; 4) a comparatively low in-
cidence of severe granulation tissue formation; and 5) the
ability to be easily beveled at an angle or cut with a side
hole to allow the stent to conform to anatomy and preserve
ventilation of adjacent lobes. This last feature is especiallyThe Journal of Thoracic and Cimportant in lung transplant recipients because of the short
distance between anastomosis and subsequent lobar bron-
chial bifurcation.
Our study demonstrated significant objective functional
improvement in patients who were managed with our ap-
proach. By using a combination of balloon dilatation, me-
chanical/laser debridement, and temporary silicone stent
placement, our patients showed a significant increase in
FEV1 (mean improvement: 41.5%, P < .01). Similarly,
FVC was increased by an average of 17.5% (P < .01)
from baseline. The larger increase in FEV1, compared with
FVC, is consistent with the obstructive nature of airway ste-
nosis, which would be expected to cause similar physiologic
changes observed in other obstructive diseases, such as
chronic obstructive pulmonary disease (COPD). The nor-
malization of FEV1/FVC ratio after therapy, from 66.3%
to 81.3%, provides further objective evidence of efficacy
with our approach.
In regard to factors that may be associated with the devel-
opment of airway stenosis, a strong correlation was found
between the presence of Aspergillus fumigatus, actinomy-
ces, and Pseudomonas aeruginosa and the subsequent oc-
currence of airway complications. The reason for this
association is not clear. We postulate that these organisms
may cause airway inflammation and scar formation at the
level of the anastomosis, particularly if they are present in
the early postoperative period. The inflammation may also
compromise blood supply to the allograft bronchus, result-
ing in ischemia and subsequent scarring. An alternative ex-
planation may be that the abnormal ischemic or stenotic
airways may predispose colonization and subsequent illness
from different infective agents.
Clearly, there are different morphologic types of airway
stenosis post-lung transplant. We propose a classificationardiovascular Surgery c Volume 136, Number 6 1573
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XTABLE 3. Follow-up After Stent Placement and Removal*
All Types Type 1 Type 2 Type 3 Type 4
Pre-Stent FEV1 (L) 1.97 2.12 2.84 1.76 0.6
Post Stent FEV1 (L) 2.76 2.89 3.00 2.97 1.33
Mean change FEV1 (L) 0.80 0.77 0.16 1.22 0.73
Pre-Stent FVC (L) 2.91 3.09 3.56 2.9 1.21
Post-Stent FVC (L) 3.42 3.58 3.59 3.79 1.59
Mean change FVC (L) 0.52 0.50 0.03 0.89 0.38
Pre-Stent FEV1/FVC (%) 66.27 68.6 79.6 61.2 78.8
Post-Stent FEV1/FVC (%) 81.28 81.3 83.7 49.3 83.4
Mean change FEV1/FVC (%) 15.01 12.77 4.1 17.65 34.1
% 3 year patency after stent
removal
100 100 100 100 NA
# Deaths within 3 years of
stent removal
1 0 1 0 NA
FEVI, Forced expiratory volume in 1 second; FVC, forced vital capacity; L, liters; NA, not applicable. *2 patients stented while on mechanical ventilation not included in analysis.system based on morphologic characteristics. The most
common type of stenosis is an isolated anastomotic narrow-
ing (type 1) without an obvious association to the underlying
lung disease. We also found preliminary evidence of an as-
sociation between isolated distal stenosis (type 3) and cystic
fibrosis. It is possible that the chronically infected proximal
airways of these patients may lead to rapid focal colonization
of the recipient lung. Finally, we believe that diffuse airway
stenosis (type 4) may be associated with prolonged hypoten-
sion in the immediate postoperative period and may require
lifelong stent placement. With better characterization of all
types of airway stenoses, we hope that more data can be gen-
erated from the transplant community to improve under-
standing of these conditions in the future.
We have adopted an aggressive approach of surveillance
bronchoscopy for all lung transplant recipients with stents
to manage and prevent complications. On average, we per-
formed bronchoscopic examinations every 3 to 4months after
stent placement and for at least 6 months after stent removal.
We also treated all cases of Aspergillus found on bronchos-
copy, often with lifelong therapy. In the past, it has been re-
ported that anastomotic strictures after lung transplant were
a lifelong problem.12 However, we found that, with our ap-
proach, most airway stenoses were curable with stenting
and treating of underlying infections, usually within a 1-
year timeframe.We show that aggressive, early stenting leads
to less long-term stricturing of the airway and ultimately to
resolution of this problem in almost all patients. Once airway
remodeling has occurred, stents could be removed and lumi-
nal patency maintained. Stenting was safely accomplished in
the presence of gross anastomotic infections and was associ-
ated with long-term improvement in FEV1. Finally, we found
that the use of studded silicone stents avoided many of the
complications of wire mesh stents and allowed us to easily re-
move the stents after the lesions matured.
Previously available tracheobronchial prostheses made of
silicone had drawbacks resulting from rigidity, wall thick-1574 The Journal of Thoracic and Cardiovascular Suness, and propensity for stent migration. Since 1996, we
have used a thin-walled expandable silicone airway stent
with external 3-mm protrusions spaced every 0.5 square
cm.13 The rounded protrusions help anchor the stent to the
bronchial wall without granulation ingrowth.14 With this
stent, we have not experienced infolding of the stent or major
stent dislodgement. However, several drawbacks to the
Hood-studded silicone stent should be pointed out. Minor
problems with stent encrustation did occur; however, these
were handled easily with flexible bronchoscopy. The occur-
rence of this problem has been minimized with a nebulized
saline airway humidification regimen and, in severe cases,
the addition of recombinant human deoxyribonuclease I
(Pulmozyme: Genetech; San Francisco, Calif) nebulized
regimen. Stent migration, although uncommon, is seen. Fi-
nally, placement and removal of these stents require rigid
bronchoscopy and general anesthesia. It should also be
noted that, in our hands, stenting in the 2 patients with dif-
fuse airway stenosis improved symptomatology but was
not curative. This challenging subset of patients required
more frequent stent manipulation and surveillance bron-
choscopy compared with patients with other post-lung trans-
plant stricture types.
Despite these caveats, short and longer segment bronchial
stenoses were effectively treated with this modality. We
were able to remove 18 of 22 stents from our patients. To
our knowledge, this is the largest published series of stent re-
moval in the adult lung transplant population. Similar
encouraging results with silicone stent removal after anasto-
motic complications in the adult lung transplant popula-
tion15 and pediatric lung transplant population16 have also
been reported in small numbers of patients.
CONCLUSIONS
Amultimodality approach to bronchial stenosis after lung
transplant, which uses balloon dilatation, debridement, and
silicone stenting, is curative in most patients. Patients withrgery c December 2008
Thistlethwaite et al Cardiothoracic Transplantationsuspected airway problems should be referred for early
bronchoscopy with the potential for stent placement. Our ex-
perience with studded silicone stents in the setting of post-
transplant airway obstruction demonstrates the safety, ease
of placement, and potential for stent removal with perma-
nent cure of bronchial stenosis. The good long-term outcome
of most of the patients in our series who were treated with
these stents justifies their expanded use for anastomotic
strictures after lung transplant.
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